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Duffy Phenotype 
and Plasmodium 
vivax infections in 
Humans and Apes, 
Africa
To the Editor: Benign tertian 
malaria, caused by Plasmodium vivax, 
has long been considered absent, or 
at least extremely rare, in western 
and central Africa. In these regions, 
95%–99% of humans are of the Duffy 
negative phenotype, a condition that is 
thought to confer complete protection 
against the parasite during the blood 
stages of its life cycle (1,2). Sporadic 
reports throughout the latter half of the 
20th century, however, have hinted at 
the presence of the parasite in these 
regions, the most convincing of 
which were the steady and consistent 
numbers of non-African travelers who 
returned to their countries of origin 
infected with malarial parasites that 
were subsequently identifi ed as P. 
vivax (2).
More recently, evidence has 
emerged regarding the transmission 
of P. vivax in regions of Africa 
where the local human population is 
predominantly Duffy negative (3–6). 
In 4 (3.5%) of 155 patients from 
western Kenya (6), 7 (0.8%) of 898 
persons from Angola (4), and 8 (8.2%) 
of 97 persons from Equatorial Guinea 
(4), P. vivax parasites were detected 
in the blood of apparently Duffy-
negative persons, suggesting that the 
parasite might not be as absolutely 
dependent on the Duffy receptor for 
erythrocyte invasion as previously 
thought. These fi ndings are supported 
by a report from Madagascar (where 
the human population is composed 
of a mixture of Duffy-positive and 
Duffy-negative persons), in which 42 
(8.8%) of 476 Duffy-negative persons 
who had symptoms of malaria were 
reported to be positive for P. vivax 
by both microscopy and PCR (7). 
The prevalence of P. vivax in Duffy-
negative persons was signifi cantly 
lower than its prevalence in Duffy-
positive persons residing in the same 
area, suggesting that Duffy negativity 
is a barrier to the parasite to some 
degree. Given the extremely high rates 
of malaria transmission in western and 
central Africa, a P. vivax parasite that 
could effi ciently invade Duffy-negative 
erythrocytes would, presumably, 
become highly prevalent very rapidly.
With the exception of the cases 
reported from Angola and Kenya, 
which lie outside the area where 
the proportion of the population 
with Duffy negativity is highest, 
the reports of the transmission of P. 
vivax within predominantly Duffy-
negative populations all come from 
regions inhabited by chimpanzees and 
gorillas (i.e., Democratic Republic 
of the Congo [3], Uganda [4], and 
Equatorial Guinea [5]). During our 
seroepidemiologic study from the 
Democratic Republic of the Congo, 
in which P. vivax sporozoite–specifi c 
antibodies were detected in ≈10% of 
the population, we found that women 
were signifi cantly more likely than 
men to have been exposed to P. vivax 
sporozoites (3). Women in this region 
typically spend more time than men 
near the forest fringe, where they work 
in crop fi elds. This forest is within the 
known habitat range of the chimpanzee 
Pan troglodytes and the gorilla, Gorilla 
gorilla gorilla, both of which have 
been reported to be natural hosts of the 
malaria parasite P. schwetzi, which is a 
P. vivax–like or P. ovale–like parasite 
that might also be unable to invade 
the erythrocytes of persons who are 
Duffy negative (8). These animals have 
recently been shown to be infected 
occasionally with parasites that have 
mitochondrial genomes closely 
resembling those of P. vivax (9,10).
We have argued that, given the 
high malaria transmission rates in sub-
Saharan Africa, it is plausible that the 
1%–5% of the human population who 
are Duffy positive might maintain 
the transmission of the parasite (2). 
The discovery of P. vivax parasites 
(or P. vivax–like parasites) in the 
blood of African great apes leads to 
a question: could nonhuman primates 
in Africa be acting as Duffy-positive 
reservoirs of P. vivax in regions 
where the human population is almost 
entirely insusceptible? This possibility 
warrants further investigation. Given 
the increasing rarity of the great 
apes, however, their capacity to act as 
zoonotic reservoirs could be limited. 
It would be informative, in any case, 
to determine how the regions that P. 
vivax–positive travelers visit during 
their stay in Africa correspond with the 
ranges of chimpanzees and gorillas.
If African great apes do, indeed, 
constitute a zoonotic reservoir of 
P. vivax parasites, what are the 
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repercussions for human health? Given 
that 95%–99% of humans possibly 
exposed to such a reservoir are Duffy 
negative, and therefore resistant to 
the parasite, these would appear to be 
slight. However, as humans encroach 
more frequently into ape habitats, the 
chances of humans encountering the 
parasite will increase. In the short 
term, the risks are probably limited 
to Duffy-positive persons who enter 
areas where apes are present, such as 
tourists and migrant workers.
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Rickettsia parkeri 
and Candidatus 
Rickettsia 
andeanae in 
Gulf Coast Ticks, 
Mississippi, USA
To the Editor: Rickettsia parkeri, 
a spotted fever group Rickettsia 
(SFGR) bacterium, is transmitted by 
Amblyomma maculatum, the Gulf 
Coast tick (1). The prevalence of R. 
parkeri in Gulf Coast ticks has been 
reported as <42% in the United States, 
which is higher than reported rates of R. 
rickettsii (the cause of Rocky Mountain 
spotted fever) in Dermacentor species 
ticks. Misdiagnosis among SFGR 
infections is not uncommon, and 
R. parkeri rickettsiosis can cause 
symptoms similar to those for mild 
Rocky Mountain spotted fever (1). We 
evaluated infection rates of R. parkeri 
and Candidatus Rickettsia andeanae, 
a recently identifi ed but incompletely 
characterized SFGR, in Gulf Coast 
ticks in Mississippi, USA.
During May–September of 2008–
2010, we collected adult Gulf Coast 
ticks from vegetation at 10 sites in 
Mississippi. We extracted genomic 
DNA from the ticks using the 
illustra tissue and cells genomicPrep 
Mini Spin Kit (GE Healthcare Life 
Sciences, Piscataway, NJ, USA). We 
tested amplifi able tick DNA by PCR of 
the tick mitochondrial 16S rRNA gene 
(2). We tested for molecular evidence 
of any SFGR species by nested PCR 
of rompA (rickettsial outer membrane 
protein A gene) (1). Samples positive 
for SFGR were subsequently tested 
by using species-specifi c rompA PCR 
for R. parkeri (3) and Candidatus R. 
andeanae (4). All PCRs included 1) a 
positive control of DNA from cultured 
R. parkeri– (Tate’s Hell strain) or 
Candidatus R. andeanae–infected Gulf 
Coast ticks and 2) a negative control 
of water (nontemplate). PCR products 
were purifi ed by using Montage 
PCR Centrifugal Filter Devices 
(Millipore, Bedford, MA, USA) and 
sequenced by using Eurofi ns MWG 
Operon (Huntsville, AL, USA). We 
generated consensus sequences using 
ClustalW2 (www.ebi.ac.uk/Tools/
msa/clustalw2/) alignment and 
identifi ed the sequences using 
GenBank BLAST searches (www.ebi.
ac.uk/Tools/clustalw2/).
Proportions of ticks infected 
with SFGR, by region and year, 
were compared separately by using 
Fisher exact test followed by pairwise 
comparisons with a Bonferroni 
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